New drug shows promise against Hard-to-Treat cancers

NCT ID NCT04225117

Ongoing Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated May 14, 2026 · Updated 33 times

Summary

This study tests an experimental drug, enfortumab vedotin, in people with advanced solid tumors that have spread. The main goal is to see if the drug can shrink tumors. About 329 adults with various solid tumors will take part. The drug is given by IV and aims to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arizona Oncology

Tucson, Arizona, 85711, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists

Fort Myers, Florida, 33901, United States
Florida Cancer Specialists

Tallahassee, Florida, 32308, United States
Florida Cancer Specialists

West Palm Beach, Florida, 33401, United States
Gettysburg Cancer Center

Gettysburg, Pennsylvania, 17375, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Indiana University Cancer Center

Indianapolis, Indiana, 46202, United States
Mary Crowley Research Center

Dallas, Texas, 75230, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10022, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
New York University Langone Health

New York, New York, 10016, United States
Northside Hospital

Atlanta, Georgia, 30342, United States
Northwestern University Medical Center

Chicago, Illinois, 60611, United States
Ohio State University

Columbus, Ohio, 43210, United States
Piedmont Hospital

Atlanta, Georgia, 30318, United States
Rutgers Cancer Institute

New Brunswick, New Jersey, 08901, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Site CA15003

Ottawa, Ontario, K1H 8L6, Canada
Site JP81001

Kashiwa, Chiba, Japan
Site JP81002

Koto, Tokyo, Japan
Site JP81003

Chūō, Tokyo, Japan
Site JP81004

Nagoya, Aichi-ken, Japan
Site JP81005

Chuo-ku, Osaka, Japan
Site JP81006

Nakatogari, Shizuoka, Japan
Site JP81007

Ōsaka-sayama, Osaka, Japan
Site JP81010

Okayama, Japan
Site JP81011

Kitaadachi-Gun, Saitama, Japan
University of California - San Francisco

San Francisco, California, 94158, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Kansas

Fairway, Kansas, 66205, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Minnesota Cancer Center

Minneapolis, Minnesota, 55455, United States
University of Texas

Houston, Texas, 77030, United States
Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS